Introduction
Shc (Src homolog and collagen homolog) proteins are adaptor molecules that contain SH2 and PTB domains (Ravichandran, 2001 ). They exist in three different isoforms with molecular masses of 46, 52 and 66 kDa. Shc proteins are conventionally known to transduce the mitogenic signals from receptor tyrosine kinases to downstream targets, such as, extracellular signalregulated kinases/mitogen-activated protein kinases (ERK/MAPK) (Ravichandran, 2001) . All the isoforms contain three functional domains -an SH2 domain, a PTB domain and a CH1 domain with three conserved tyrosine residues that are phosphorylated with respect to various signals (Ravichandran, 2001) . Additionally, p66 Shc has a unique CH2 domain at the N-terminus of the protein, which contains a serine residue that could be phosphorylated under stress signals (Migliaccio et al., 1999) .
Different members of the Shc proteins exhibit distinct expression patterns and biological functions. For example, p52
Shc and p46 Shc are expressed in most of the cells, while p66
Shc protein is expressed predominantly in epithelial cells (Migliaccio et al., 1997) . Both p52 Shc and p66 Shc are distributed throughout the cytosol, whereas p46
Shc localizes to mitochondria . Nevertheless, recent studies indicate that in response to stress signals, such as, H 2 O 2 treatment, a fraction of cytosolic p66
Shc is translocated to mitochondria, where it is associated with heat-shock protein to mediate apoptotic response (Orsini et al., 2004) . Despite that p66 Shc , like p52 Shc 
/p46
Shc , is phosphorylated at its tyrosine residues during epidermal growth factor (EGF) treatment and forms complexes with Grb-2, there are certain functional differences between p66 Shc and the other two Shc members. First, p66 Shc 
, unlike p52
Shc , could not transform NIH3T3 mouse fibroblast cells in vitro (Migliaccio et al., 1997) . Second, overexpression of p66
Shc protein in cell lines, such as, HeLa, CHO and COS-1 cells, does not increase EGFinduced ERK/MAPK activation (Migliaccio et al., 1997; Okada et al., 1997) . Third, p66 Shc is phosphorylated at Ser 36 in its CH2 domain under various stress signals such as H 2 O 2 , UV radiation and exposure to chemicals, such as, Taxol, and thus could serve as an apoptotic sensitizer to stress signals (Migliaccio et al., 1999; Yang and Horwitz, 2000) . Finally, p66 Shc acts as a negative regulator of human and mouse T-cell survival and proliferation (Pacini et al., 2004) and has been implicated in the control of lifespan in mammals (Migliaccio et al., 1999) . Thus, data from the above studies clearly indicate p66
Shc as a transducer of signals in response to cellular stress. However, its role in human carcinogenesis is not understood.
In human carcinoma cells, p66 Shc may be involved in regulating their proliferation. Among ErbB-2-positive ovarian cancer cell lines, a positive correlation between p66
Shc and ErbB-2 is observed (Xie and Hung, 1996) . In breast cancer cell lines, elevated expression of p66 Shc protein is observed in those with highly metastatic ability and similar phenomenon is seen in lymph nodepositive breast tumors (Jackson et al., 2000) . However, another study shows that p66
Shc protein level inversely correlates with the expression of ErbB-2, a prognostic marker for breast cancer cell lines (Xie and Hung, 1996) . Additionally, studies on archival breast cancer specimens have showed that the expression of p66
Shc protein inversely correlates with the relapse of breast cancer (Davol et al., 2003) . Hence, the role of p66
Shc in carcinogenesis requires further investigations.
We previously showed that sex steroid hormones including estrogens and androgens upregulate p66 Shc protein level in human carcinoma cell lines (Lee et al., 2004a) . These data suggest the role of p66
Shc protein in sex hormone-regulated cancer cell proliferation. Furthermore, p66
Shc level is significantly elevated in cancerous cells compared to the neighboring noncancerous cells in clinical archival prostate cancer (PCa) specimens (Lee et al., 2004a) . Therefore, p66
Shc might play a role in the development and/or progression of PCa. Hence, in this study, we explored the role of p66 Shc in the regulation of PCa cell proliferation that could lead to cancer progression.
Results

Expression of p66
Shc protein in different human PCa cell lines Based on our previous observations on archival PCa specimens that p66
Shc protein level is elevated in cancerous cells, we analysed the expression profile of p66
Shc in different PCa cell lines, which exhibit different growth rates. As shown in Figure 1 Shc protein alone (Figure 1 ). p66
Shc protein levels in the rapid-growing cells were approximately 4-13-fold higher than that in slowgrowing LNCaP C-33 cells and over 10-fold higher than in MDA PCa2b cells. Interestingly, among those PCa cells, the p66
Shc protein level inversely correlated with the expression level of cellular form of prostatic acid phosphatase (cPAcP) (Figure 1 ), the major protein tyrosine phosphatase and a negative growth regulator in prostatic epithelia (Lin et al., , 2001 .
To examine further the correlation of p66 Shc protein expression with cell growth, we analysed p66
Shc protein level in different passages of LNCaP cells, utilizing Ab recognizing all the three isoforms of Shc protein. As reported earlier Igawa et al., 2002) , the growth ratio of C-81 cells was approximately three times higher than that of C-33 cells, while C-51 cells exhibit a growth rate faster than C-33 cells but slower than C-81 cells (Figure 2a ). Western blot analyses revealed that p66
Shc protein expression was higher in C-81 cells than in Figure 1 Expression of p66 Shc protein in different PCa cells. LNCaP C-33, PC-3, TSU-Pr1 and DU 145 cells were plated in a medium supplemented with 5% fetal bovine serum (FBS), while MDA PCa2b cells were plated in a medium containing 20% FBS for the experiments. An aliquot of total cell lysates from MDA PCa2b (MDA), LNCaP C-33 (LN), PC-3 (PC), TSU-Pr1 (TSU), and DU145 (DU) cells was electrophoresed, transferred to nitrocellulose membranes, and incubated with Abs against Shc, p66
Shc and cPAcP proteins, respectively. The level of b-actin protein was detected as an internal loading control. The intensity of hybridization band was semiquantified using a densitometer. The relative level of p66
Shc protein to the corresponding b-actin protein was calculated and then normalized to that of LNCaP C-33 cells. The ratio was shown at the bottom of the figure. Similar results were observed in three sets of independent experiments. The doubling time of each cell line has been given as a measure of their growth rates ( a Navone et al., 1997;  b Horoszewicz et al., 1983; Kaighn et al., 1979;  d Iizumi et al., 1987;  e Stone et al., 1978) p66 Shc protein in human prostate cancer cell proliferation S Veeramani et al C-51 and C-33 cells, whereas p52 Shc protein level was approximately similar in all cells (Figure 2a , inner panel). Since Shc family members are tyrosine phosphorylated in mediating the growth signals from tyrosine phosphorylated receptor tyrosine kinases (Ravichandran, 2001; Lee et al., 2004b) Lee et al., 2004b) . Similar negative results were obtained by using the antibody against pY239 or pY317 of p52 Shc that could also react with the corresponding sites in p66
Shc protein with the total cell lysate proteins (Lee et al., 2004b) . Nevertheless, cPAcP was highly expressed in C-33 cells, while it was only barely detected in C-81 cells, thus, inversely correlating with their relative p66 Shc protein levels ( Figure 2a , inner panel). Similarly, MDA PCa2b cells of passage number 60 (MDA p60) grew faster than those of passage number 40 (MDA p40) (Figure 2b ). Concurrently, MDA p60 cells expressed a higher level of p66
Shc protein than MDA p40 cells (Figure 2b, inner panel) . The low level of p66
Shc protein in MDA p40 cells could be detected only after prolonged exposure (data not shown). Furthermore, the elevated level of p66
Shc protein in MDA p60 cells corresponded to the decreased cPAcP protein (Figure 2b, inner panel) . Thus, the data collectively indicate that the expression level of p66 Shc protein correlates, positively with PCa cell proliferation rate and, inversely with cPAcP expression.
Effects of growth manipulation on p66
Shc protein level in different PCa cells
Since p66
Shc protein level positively correlates with the PCa cell growth, we analysed whether manipulation of PCa cell growth would alter the expression level of p66 Shc protein. We used EGF and 5a-dihydrotestosterone (DHT), which could upregulate the proliferation of LNCaP C-33 cells and downregulate the cPAcP (Lin et al., 1992 Meng and Lin, 1998; Lee et al., 2004b) , and examined their effects on the protein levels of p66 Shc in those cells. As shown in Figure 3a , p66
Shc protein level was upregulated in LNCaP C-33 cells treated for 24 h with 10 ng/ml EGF or 10 nM DHT, approximately 2.5-3-fold higher than that in the corresponding control cells.
Owing to the inhibitory effect of cPAcP on PCa cell proliferation (Lin et al., , 2001 , we examined whether increased proliferation by inhibiting cPAcP activity would lead to the elevation of p66
Shc protein in those cells. LNCaP C-33 cells that express endogenous cPAcP were exposed to different concentrations of L( þ )-tartrate, a classical inhibitor of PAcP (Lin et al., 1992; Meng and Lin, 1998) . In the presence of 2.5 mM L( þ )-tartrate, the expression level of p66 Shc protein was elevated by approximately 2.5-fold (Figure 3b ), corresponding to the decrease in cPAcP activity (data not shown). 5 mM L( þ )-tartrate had the similar effect as 2.5 mM concentration. Furthermore, the increase of p66 Shc in L( þ )-tartrate-treated cells correlated with increased ERK/MAPK activation ( Figure 3b ) and cell proliferation (data not shown). It should be noted that L( þ )-tartrate had no effect on the levels of p52
Shc and p46
Shc proteins. Thus, elevated p66 Shc protein level correlates with ERK/MAPK activation as well as cell proliferation in cPAcP-inhibited PCa cells.
As an additional approach, we examined the p66 Shc protein expression in PAcP cDNA-transfected stable subclones of LNCaP C-81 cells that have reduced proliferation rates (Lin et al., , 2001 Meng and Lin, 1998 Shc protein in human prostate cancer cell proliferation S Veeramani et al compared to C-81 parental ( Figure 4a ). Similarly, PAcP cDNA-transfected PC-3 stable subclone cells that had slower growth rates compared to their parental cells Meng and Lin, 1998 ) also expressed lower levels of p66
Shc protein than their parental cells ( Figure 4b ). Taken together, the results indicated that manipulation of PCa cell growth leads to a corresponding change in p66
Shc expression level. Shc and V-1 and LNCaP C-33 cells (data not shown). As shown in Figure 5a To further confirm the role of p66 Shc in PCa cell growth regulation, we determined whether downregulation of p66
Shc protein, using a plasmid-based RNAi Shc protein in human prostate cancer cell proliferation S Veeramani et al approach, would lead to a decrease in their growth rate.
We transfected LNCaP C-81 and PC-3 cells with pSUPp66 to knock down their p66 Shc expression. In order to normalize the differences in the transfection efficiency of those cells, we cotransfected with pTRACER-CMV along with pSUP-p66. As shown in Figure 6a Shc protein in human prostate cancer cell proliferation S Veeramani et al that they exhibited approximately 30% decrease in their proliferation rates than the vector-alone transfected cells, as indicated by the decrease in the percentage of cell population in the S phase of cell cycle, that is, 14.8% for p66
Shc -knocked-down cells vs 22.6% for vectoralone-transfected cells (Figure 6b) . Similarly, in PC-3 cells, an approximately 45% knock-down of p66 Shc protein by RNAi led to the decrease in ERK/MAPK activation, as indicated by its decreased phosphorylation (Figure 6c , left panel) that correlated with approximately 35% reduction in their proliferation rate as determined by the cell counting (Figure 6c, right panel) .
Cell cycle analysis of those p66
Shc -knocked-down PC-3 cells showed that there was a decrease in S phase from 18.3% in vector-alone-transfected cells to 13.6% for p66
Shc -knocked-down cells (Figure 6d) . Thus, the data collectively indicate that p66
Shc protein plays a critical role in regulating the proliferation of PCa cells.
Discussion
Shc proteins play a critical role in regulating PCa cell proliferation, in part by mediating tyrosine phosphorylation Shc -knocked-down LNCaP C-81 cells. 7.5 Â 10 5 LNCaP C-81 cells were plated in regular medium on 100 mm dishes and transfected with pSUP-p66. Control cells were transfected with vector alone (Vec). After 3 days, cells were trypsinized, fixed with 70% ethanol and stained with propidium iodide. Cells were analysed with a flow cytometer for the distribution of cell cycle. Cells were cotransfected with pTRACER-CMV for estimating the transfection efficiency. The figure is a representative of three sets of independent experiments. (c) Western blot and cell growth analyses of p66
Shc -knocked-down PC-3 cells. PC-3 cells were transfected with pSUP-p66, as described for LNCaP C-81 cells. Cell growth was analysed 3 days post-transfection. To normalize the transfection efficiency, cells were cotransfected with pTRACER-CMV. The figure is a representative of two sets of independent experiments performed in duplicates. (d) Cell cycle analysis of p66
Shc -knocked-down PC-3 cells. 7.5 Â 10 5 PC-3 cells were plated in regular medium on 100 mm dishes and transfected with pSUP-p66. Control cells were transfected with vector alone. To normalize the transfection efficiency, cells were cotransfected with pTRACER-CMV. After 3 days, cells were trypsinized, fixed with 70% ethanol and stained with propidium iodide. Cells were analysed with a flow cytometer for the distribution of cell cycle. The figure is a representative of two sets of independent experiments p66 Shc protein in human prostate cancer cell proliferation S Veeramani et al signals. For example, treatment of LNCaP C-33 cells with androgens leads to increased phosphorylation of p52 Shc at Y317 residue, which is required for DHTinduced proliferation, but not that of EGF (Lee et al., 2004b) . Apart from p52
Shc , the role of other Shc members in the proliferation of PCa cells remains an enigma. Interestingly, androgen stimulation of PCa cells is accompanied with the upregulation of p66 Shc protein levels, but not its tyrosine phosphorylation levels (Lee et al., 2004a, b;  Figure 3a) . Furthermore, p66
Shc protein level is significantly elevated in archival human PCa specimens, higher in the cancerous cells compared to the adjacent noncancerous cells (Lee et al., 2004a) . Hence, we hypothesize that p66
Shc protein is also involved directly in the regulation of PCa cell proliferation.
Our data in different PCa cell lines clearly show that p66
Shc protein level, but not p52 Shc or p46 Shc protein levels, consistently correlates with cell proliferation (Figures 1-4) . Additionally, elevated expression of p66 Shc protein by cDNA transfection in LNCaP C-33 cells correlates with increased cell proliferation ( Figure 5 ).
Conversely, knock-down of p66
Shc protein level by its siRNA leads to decreased cell growth (Figure 6 ). Our cell line data corroborate our observations on the archival PCa tissue specimens that p66
Shc expression is lower in benign glandular cells, whereas in adjacent adenocarcinomatous cells, the expression of p66 Shc is higher (Lee et al., 2004a (Figure 5a, right panel) . This is comparable to the rapid-growing PCa cells, such as PC-3, TSU-Pr1 and DU 145 cells, which express increasingly higher levels of p66 Shc protein, but still have a similar doubling time (Figure 1) . Collectively, the data support our hypothesis that elevated p66
Shc protein in prostate carcinomas plays a critical role in upregulating Similarly, elevation of p66 Shc protein is observed in breast cancer specimens, where p66
Shc protein is elevated in the lymph node-positive breast carcinomas (Jackson et al., 2000) . Nevertheless, other studies show that the level of p66
Shc protein in relapsed breast cancers is decreased, significantly lower than that in primary, nonrelapsed tumors (Davol et al., 2003) . The data collectively implicate that p66
Shc protein plays a role in the tumorigenicity of those breast cancer cells, although the correlative relationship requires further clarification. It should be noted that the level of p66
Shc protein in human carcinoma cells is altered by various treatments including steroids and growth factors (Figure 3a ; Lee et al., 2004a) . Hence, it is possible that the inconsistency in the correlativity in breast cancer studies may partly be related to the different treatment regimens that those patients were in, prior to obtaining the specimens. As described, some of those relapsed tumors had been obtained from patients who were under adjuvant hormonal therapy (Davol et al., 2003) . It is thus expected that those hormone-ablated specimens would have a decreased level of p66 Shc protein. In such case, a substantial number of cancer specimens that have low levels of p66
Shc protein may tip the results of statistical analyses. Nevertheless, due to the small sample size in our study, we are unable to determine if the elevated p66
Shc protein level could serve as a surrogate marker for PCa progression. The clinical application of p66 Shc protein in PCa deserves further investigations.
The molecular mechanism by which p66 Shc protein is involved in regulating cell proliferation deserves careful analyses. In PCa cells, p66
Shc protein level inversely correlates with cPAcP and positively correlates with ERK/MAPK activation. In p66
Shc cDNA-transfected stable subclone cells, ERK/MAPKs are activated, correlating with increased cell proliferation ( Figure 5 ).
Conversely, in p66
Shc -knocked-down LNCaP C-81 and PC-3 cells, ERK/MAPKs are inhibited that correlate with decreased cell proliferation (Figure 6 ). This p66 Shc -activated ERK/MAPK in p66
Shc cDNA-transfected LNCaP cells is consistent with the observations that in cPAcP-inhibited LNCaP C-33 cells by L( þ )-tartrate, p66
Shc protein level is elevated and ERK/MAPK are activated (Figure 3b) . We propose that the negative effect of cPAcP on p66
Shc protein level is not through a direct mechanism, such as cPAcP-p66
Shc protein interaction, although it requires further investigation. It should be noted that the inverse correlation of the level of cPAcP to p66
Shc and ERK/MAPK phosphorylation is clinically significant, because in clinical PCa specimens, cPAcP is decreased (Loor et al., 1981; Pontes et al., 1981; Solin et al., 1990; Sakai et al., 1993; Lin et al., 2001) and p66 Shc protein level and ERK/MAPK phosphorylation are elevated (Gioeli et al., 1999; Price et al., 1999; Lee et al., 2004a ). This phenomenon is also similar to the observation in breast cancer cells that increased expression of p66
Shc protein correlates with ERK/MAPK activation (Jackson et al., 2000) . The observation that elevated p66
Shc protein reduces the degree of EGF-induced ERK/MAPK activation in HeLa, CHO or COS-1 cells (Migliaccio et al., 1997; Okada et al., 1997) (Trinei et al., 2002; Pacini et al., 2004) . Interestingly, treatment of cells with steroid hormones and growth factors, such as, DHT and EGF, results in the upregulation of ROS in those cells (Ripple et al., 1997 (Ripple et al., , 1999 Meng et al., 2002) and the increased ROS could serve as a positive regulator of cell growth as observed in human hepatoma cells (Liu et al., 2002) . Importantly, around 80% of the prostate tumor specimens showed an increase in NADPH oxidase 1 and intracellular ROS levels when compared to the adjacent noncancerous tissue (Lim et al., 2005) . Thus, it could be speculated that the upregulation of p66 Shc protein by DHT or EGF treatment in PCa cells might be through the upregulation of ROS in those stimulated cells. In summary, our data clearly support for a novel functional role of p66 Shc protein in prostate carcinogenesis probably through promoting cell proliferation, although the detailed molecular mechanism(s) by which p66 Shc protein upregulates PCa cell proliferation require(s) further studies. Further, the potential role for p66 Shc protein in serving as a target for PCa therapy deserves further investigations.
Materials and methods
Materials
FBS, RPMI 1640 culture medium, glutamine and gentamicin were purchased from Invitrogen (Carlsbad, CA, USA). Charcoal/dextran-treated, certified FBS was obtained from HyClone (Logan, UT, USA). BRFF-HPC1 medium was obtained from Athena Environment Science, Inc. (Baltimore, MD, USA). Polyclonal Abs (#06-203) recognizing all three isoforms of Shc protein and the Ab (#07-150) specifically recognizing p66
Shc protein were from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Rabbit anti-PAcP antiserum was obtained as described previously (Lin et al., 1993) . Polyclonal Abs against phospho-ERK/MAPK (Thr202/ Tyr204) and ERK/MAPK were from Cell Signaling (Beverly, MA, USA). Anti-b-actin Ab, EGF and DHT were obtained All other chemicals were as described previously Meng and Lin, 1998; Lee et al., 2004a, b) Cell culture
Human prostate carcinoma cell lines including LNCaP-FGC (doubling time 60 h) (Horoszewicz et al., 1983) , MDA PCa2b (doubling time 61-73 h) (Navone et al., 1997) , DU 145 (doubling time 34 h) (Stone et al., 1978) and PC-3 (doubling time 33 h) (Kaighn et al., 1979) were purchased from the American Type Culture Collection (Rockville, MD, USA). TSU-Pr1 cells (doubling time 36 h) (Iizumi et al., 1987) were obtained from Dr Jin-Tang Dong at Emory University School of Medicine (Atlanta, GA, USA). Human PCa cells except MDA PCa2b cells were routinely maintained in the regular culture medium, that is, phenol red-positive RPMI 1640 medium supplemented with 5% FBS, 1% glutamine and 0.5% gentamicin . Cells were split once per week, which was defined as one passage. LNCaP cells with passage numbers less than 33 were designated as C-33, those with numbers greater than 81 as C-81, and those with numbers between 34 and 80 as C-51 Meng et al., 2000; Igawa et al., 2002) . LNCaP C-33 cells express endogenous PAcP, while C-81 cells have lost PAcP expression . PAcP-cDNA-transfected C-81 stable subclone cells, that is, LN-23 and LN-40 cells, have slower growth rates (doubling time 72 and 90 h, respectively) than C-81 parental cells (doubling time 49 h) in a steroid-reduced condition . PC-3 cells do not express endogenous PAcP (Kaighn et al., 1979; Lin et al., 1998) . PC-411 and PC-416 cells were PAcP cDNA-transfected PC-3 stable subclone cells with doubling time 40 and 54 h, respectively . MDA PCa2b cells were routinely maintained in the culture medium, that is, BRFF-HPC1 medium supplemented with 20% FBS, 1% glutamine and 0.5% gentamicin. For EGF or DHT treatment, LNCaP C-33 cells were steroid-starved for 48 h in a steroid-reduced medium, that is, phenol red-free RPMI 1640 medium containing 5% charcoal/dextran-treated, heat-inactivated certified FBS, 1% glutamine and 0.5% gentamicin. Cells were then exposed to EGF (10 ng/ml) or DHT (10 nM) for 24 h.
Cell growth determination
To determine the growth of different passages of LNCaP and MDA PCa2b cells, 3.2 Â 10 4 of different LNCaP cells or 1 Â 10 5 of different MDA PCa2b cells were seeded on six-well culture plates with duplicate wells and maintained in their respective culture medium. After 3 days, one set of attached cells was harvested and counted as day 0 with a Z1 model Coulter Counter (Coulter Corporation, Miami, FL, USA). The remaining attached cells were fed with fresh medium, and the total cell numbers were counted on days 2, 4 and 6 for LNCaP cells or day 3, 5 and 7 for MDA PCa2b cells. The fresh medium was added to the remaining LNCaP cells on days 2 and 4 or MDA PCa2b cells on days 3 and 5.
Immunoblotting Subconfluent cells were harvested by scraping. After being spun at 41C, the pelleted cells were rinsed with ice-cold 20 mM HEPES-buffered saline, pH 7.0, and then lysed in ice-cold cell lysis buffer containing protease and phosphatase inhibitors. The detailed protocols for immunoblotting were as described previously (Lin et Shc protein and subsequently selected by G418, as described previously . Two stable subclone cell lines, S32 and S36, were established and characterized in this study. V-1 cells were a subclone cell line of LNCaP C-33 cells transfected with the vector alone.
Flow cytometry
For experiments, cells were seeded at a density of 5 Â 10 5 cells per T25 flask in the regular medium for 3 days. At 48 h after feeding with fresh medium, cells were trypsinized, harvested and washed twice by Hank's balanced salt solution. Cells were treated with 70% ethanol at 41C for 1 h, washed with PBS, and spun down by centrifugation. The DNA of ethanol-fixed cells was stained by the PI staining reagent at 41C for 30 min. The PI staining reagent was prepared in PBS, pH 7.4, containing 0.1% Triton X-100, 0.1 mM EDTA disodium salt, 0.05 mg/ml RNase A (50 U/mg), and 50 mg/ml propidium iodide (Telford et al., 1991) . The determination of cell cycle distribution for single cell was carried out using a Becton-Dickinson fluorescence-activated cell sorter (FACSCalibur, Becton Dickinson, San Jose, CA, USA) at the UNMC Flow Cytometry Core Facility.
Construction of vector coding for p66
Shc siRNA transcripts and transfection
To knock down p66
Shc expression in PCa cells, pSUPER vector (OligoEngine Inc., USA) was used, which involves a plasmidbased RNAi approach. Sense and antisense strand oligonucleotides that code for p66
Shc siRNA transcripts were designed, according to the instructions by OligoEngine Inc., USA, and were synthesized in the Molecular Biology core facility at UNMC. The target sequence was 5 0 -TGAGTCTCTGT CATCGCTG-3 0 that lies in the CH 2 region of p66 Shc protein in human prostate cancer cell proliferation S Veeramani et al pSUPER plasmid using LipofectAmine Plus reagent (Invitrogen, USA). After 4 h, cells were replenished with RPMI-1640 medium containing 10% FBS overnight and then fed with regular medium. The cells were harvested after 3 days by trypsinization and were counted using a Coulter counter. Owing to the differences in transfection efficiency of those cells, we cotransfected them with pSUP-p66 and pTRACER-CMV, a plasmid expressing full-length GFP (Invitrogen Inc., USA), in the ratio of 3 : 1. Cells were harvested after 3 days for analysis of cell growth and cell cycle.
Abbreviations
Ab, antibody; cPAcP, cellular form of prostatic acid phosphatase; DHT, 5a-dihydrotestosterone; ECL, enhanced chemiluminescence; EGF, epidermal growth factor; ERK/ MAPK, extracellular signal-regulated kinases/mitogen-activated protein kinases; FBS, fetal bovine serum; GFP, green fluorescent protein; PCa, prostate cancer; ROS, reactive oxygen species.
